$PHAR News
Last published 20h ago
- 20h agoPHARPharming to participate in fireside chat at Jefferies Global Healthcare Conference in LondonGlobeNewswirePharming to participate in fireside chat at Jefferies Global Healthcare Conference in London on Wednesday Nov. 18 at 9:30 am GMT. Webcast will be available
- 5d agoPHARMHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.GlobeNewswireApproval extends existing U.K. indication for Joenja to eligible children aged 4 to 11 who weigh at least 27 kgJoenja is expected to become available to patients covered by the expanded indication in February 2027Marks
- 5d agoPHARMHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.GlobeNewswireMHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K. Approval extends existing U.K....
- 2w agoPHARPharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in NovemberGlobeNewswireThird quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectationsRUCONEST® revenue increased by 14% to US$93.8 million, compared to third quarter 2025,
- 2w agoPHARPharming Group announces third quarter 2026 revenues above market expectationsGlobeNewswireThird quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025Third quarter 2026 total operating expenses of approximately US$74.6 million, in line with third quarter
- 4w agoPHARPharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026GlobeNewswireFirst clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulationLeniolisib was well-tolerated, with benefits
- 1mo agoPHARMPHARPharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026GlobeNewswireLeniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to report topline results
- 2mo agoPHARMPHARFDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.GlobeNewswireFDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kgNewly approved Joenja doses are expected to be
- 2mo agoPHARMPHARPharming Group to participate in September investor conferencesGlobeNewswireLeiden, the Netherlands, September 9, 2026: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) today announced that its management will participate in the following investor conferences in the month of September:
- 3mo agoPHARMPHARPharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and olderGlobeNewswireLaunch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan
- 3mo agoPHARMPHARPharming Group to participate in Canaccord Genuity 46th Annual Growth ConferenceGlobeNewswireLeiden, the Netherlands, August 4, 2026: Pharming Group N.V. (NASDAQ:PHAR), today announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12-13, 2026. Michael Levitan, VP
- 3mo agoPHARMPHARPharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic useGlobeNewswireFor investor audiences and media only Second quarter 2026 total revenues decreased by 3% to US$90.2 million, compared to the second quarter 2025RUCONEST® revenue was US$72.3 million, a 10% decrease compared to the
- 3mo agoPHARMPHARPharming Group to report second quarter and first half 2026 financial results and provide business update on July 30GlobeNewswireLeiden, the Netherlands, July 16, 2026: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2026 and
- 5mo agoPHARPharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDSGlobeNewswireIf approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Supplemental New Drug Application
- 5mo agoPHARPharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New YorkGlobeNewswireLeiden, the Netherlands, June 2, 2026: Pharming Group ("Pharming") (NASDAQ:PHAR) today announced its participation in the 2026 Jefferies Global Healthcare Conference in New York on June 3-4, 2026. Fabrice Chouraqui,
- 5mo agoPHAREuropean Commission grants marketing authorization to Pharming's Joenja® (leniolisib) – the first approved treatment for APDS in the European UnionGlobeNewswireJoenja® (leniolisib) is first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency, in adult and pediatric patients aged 12
- 6mo agoPHARPharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disordersGlobeNewswireLeiden, the Netherlands, May 7, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS), taking place May
- 6mo agoPHARPharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026GlobeNewswireFirst quarter 2026 total revenues were US$72.4 million, an 8% decrease compared to the first quarter 2025RUCONEST® revenue was US$58.4 million, a 15% decrease compared to the first quarter 2025, mainly due to
- 6mo agoPHARPharming Group to report first quarter 2026 financial results and provide business update on May 7GlobeNewswireLeiden, the Netherlands, April 23, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the first quarter 2026 and provide a
- 7mo agoPHARPharming Group to participate in April investor conferencesGlobeNewswireLeiden, the Netherlands, April 7, 2026: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) today announced that its management will participate in the following investor conferences in the month of April: 25th Annual
- 7mo agoPHARPharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and olderGlobeNewswireIf approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiencyDecision based
- 7mo agoPHARPharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and olderGlobeNewswireFirst approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Approval is based on positive Phase III data from multinational and Japanese studies in patients aged 12 years and
- 8mo agoPHARPharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12GlobeNewswireLeiden, the Netherlands, February 26, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the fourth quarter and full year
- 8mo agoPHARPharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswireLeiden, the Netherlands, February 17, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) today announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held
- 9mo agoPHARPharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor DayGlobeNewswireHighlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces napazimone
- 9mo agoPHARPharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDSGlobeNewswireLeiden, the Netherlands, February 1, 2026: Pharming Group ((Euronext: PHARM, NASDAQ:PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental
- 10mo agoPHARPharming Group reports preliminary 2025 revenues and announces Investor DayGlobeNewswireLeiden, The Netherlands, January 8, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor
- 11mo agoPHARPharming Group to participate in Oppenheimer Movers in Rare Disease SummitGlobeNewswireLeiden, the Netherlands, December 8, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025 in New York City. This
- 1y agoPHARPharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flowGlobeNewswireTotal third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting
- 1y agoPHARPharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in LondonGlobeNewswireLeiden, the Netherlands, October 30, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming management will participate in the Jefferies Global Healthcare Conference in London, UK, on November
- 1y agoPHARPharming Group to report third quarter 2025 financial results and provide business update on November 6GlobeNewswireLeiden, the Netherlands, October 23, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the third quarter 2025 and provide a business
- 1y agoPHARPharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolioGlobeNewswireLeiden, the Netherlands, October 20, 2025: Pharming Group N.V. ("Pharming" or "the Company") ((Euronext: PHARM, NASDAQ:PHAR) today announced that 12 abstracts have been accepted for presentation at the American College
- 1y agoPHARPharming Group provides update on previously announced G&A expense reduction planGlobeNewswireLeiden, the Netherlands, October 6, 2025: Pharming Group N.V. ("Pharming" or "the Company") ((Euronext: PHARM, NASDAQ:PHAR) today announced the implementation of an organizational restructuring to accelerate the
- 1y agoPHARPharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 yearsGlobeNewswireIf approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiencyDecision based on positive data from
- 1y agoPHARPharming Group promoted to the Euronext AMX® indexGlobeNewswireLeiden, the Netherlands, September 10, 2025: Pharming Group N.V. ("Pharming" or "the Company") ((Euronext: PHARM, NASDAQ:PHAR) today announced that it has been promoted from the Euronext AScX® (Small Cap) to the
- 1y agoPHARPharming Group to present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireLeiden, the Netherlands, September 3, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming management will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York
- 1y agoPHARPharming Group appoints Kenneth Lynard as Chief Financial OfficerGlobeNewswireLeiden, the Netherlands, September 2, 2025: Pharming Group N.V. ("Pharming" or "the Company") ((Euronext: PHARM, NASDAQ:PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective
- 1y agoPHARPharming Group to participate in August investor conferenceGlobeNewswireLeiden, the Netherlands, August 4, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming's management will participate in the following investor conference in the month of August: Canaccord
- 1y agoPHARPharming Group N.V. (PHAR) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoPHARPharming Group reports second quarter and first half 2025 financial results and provides business updateGlobeNewswireSecond quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased
- 1y agoPHARPharming Group to report second quarter and first half 2025 financial results and provide business update on July 31GlobeNewswireLeiden, the Netherlands, July 17, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2025 and provide a
- 1y agoPHARPharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosisGlobeNewswireFor media and investors only Researchers identified variants which may cause activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Results enable clinical genetic testing labs to appropriately reclassify
- 1y agoPHARPharming Group reports first quarter 2025 financial results and provides business updateGlobeNewswireFirst quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting
- 1y agoPHARPharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)GlobeNewswireLeiden, the Netherlands, April 25, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the
- 1y agoPHARPharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDSGlobeNewswireFor media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated
- 1y agoPHARPharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulationGlobeNewswireMulti-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate clinical
- 1y agoPHARPharming Group reports fourth quarter and full year 2024 financial results and provides business updateGlobeNewswireFull year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth Fourth quarter 2024 total revenues
- 1y agoPHARPharming Group reports on results of the 2025 Extraordinary General Meeting of ShareholdersGlobeNewswireLeiden, the Netherlands, March 4, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM
- 1y agoPHARPharming Group to participate in March investor conferenceGlobeNewswireLeiden, the Netherlands, February 28, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming's management will participate in the following investor conference in the month of March: 37th Annual
- 1y agoPHARPharming Group to report fourth quarter and full year 2024 financial results on March 13GlobeNewswireLeiden, the Netherlands, February 27, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2024 financial results, for the period ended